

DIAGNOSE RESPIRATORY INFECTIONS WITH THE BIOFIRE® EXPANDED RESPIRATORY PANEL

The CDC estimates that during the 2018-19 Influenza (flu) season, there were approximately 37.4 to 42.9 million flu illnesses, contributing to 17.3 to 20.1 million flu-related medical visits and between 531,000 to 647,000 flu-related hospitalizations.¹ Many infections present with similar signs and symptoms, making it difficult to distinguish flu from other viral or bacterial respiratory illnesses.

BIOFIRE EXPANDED RESPIRATORY PANEL

BioReference's BioFire Expanded Respiratory Panel enables healthcare providers to improve patient care by providing comprehensive testing for diagnosis and treatment for upper respiratory infections. The panel simultaneously detects 17 viral and 4 bacterial infectious agents that present with similar symptoms.

IMPROVED CLINICAL OUTCOMES

The BioFire Expanded Respiratory Panel may significantly reduce the duration of antibiotic use, the length of inpatient stay and the time patients spend in isolation.² Improved clinical outcomes can result in cost savings, as well as increased patient satisfaction.^{3,4}



VIRUSES TESTED

- Adenovirus
- Coronavirus HKU1
- Coronavirus NL63
- Coronavirus 229E
- Coronavirus OC43
- Human Metapneumovirus
- Human Rhinovirus/
Enterovirus
- Influenza A
- Influenza A/H1
- Influenza A/H3
- Influenza A/H1-2009
- Influenza B
- Parainfluenza Virus 1
- Parainfluenza Virus 2
- Parainfluenza Virus 3
- Parainfluenza Virus 4
- Respiratory Syncytial Virus

BACTERIA TESTED

- Bordetella pertussis
- Bordetella parapertussis
- Chlamydia pneumoniae
- Mycoplasma pneumoniae

When ordering tests, providers should only order tests that are medically necessary for the diagnosis or treatment of a patient, generally not for screening. Only a few screening tests are covered by most government and third party payors for certain conditions at specific intervals.

TEST HIGHLIGHTS

Test Name	Expanded Respiratory Panel
Test Code	L740
Turnaround Time	2 Days
Specimen Requirements	Swab-Viral Culturette
Storage Requirements	Refrigerate
Methodology	Polymerase Chain Reaction
CPT Code	87486x1, 87581x1, 87633x1 and 87798x1
Clinical Utility	Assess for various viral and bacterial infectious agents associated with symptomatic upper respiratory infections.

REFERENCES:

1. Centers for Disease Control and Prevention. 2018-2019 U.S. Flu Season: Preliminary Burden Estimates. <https://www.cdc.gov/flu/about/burden/preliminary-in-season-estimates.htm>. Accessed July 16, 2019
2. Schreckenberger, PC, McAdam, AJ. 2015. Point-counterpoint: Large multiplex PCR panels should be first-line tests for detection of respiratory and intestinal pathogens. *J Clin Microbiol* 53:3110-3115.
3. Rogers, BB, Shankar, P, Jerris, RC, Kotzbauer, D, Anderson, EJ, Watson, JR, O'Brien, LA, Uwindatwa, F, McNamara, K, Bost, JE. 2015. Impact of a rapid respiratory panel test on patient outcomes. *Arch Pathol Lab Med* 139:636-641.
4. Xu, M, Qin, X, Astion, ML, Rutledge, JC, Simpson, J, Jerome, KR, Englund, JA, Zerr, DM, Migita, RT, Rich, S, Childs, JC, Cent, A, Del Beccaro, MA. 2013. Implementation of filmarray respiratory viral panel in a core laboratory improves testing turnaround time and patient care. *Am J Clin Pathol* 139:118-123.
5. Overall performance calculated for BioFire RP2. Data on file, BioFire Diagnostics.